Evidence map›Paper›PMID 29492753›Full record

Trial reportJournal of cancer survivorship : research and practice2018

Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.

Ilana Graetz, Caitlin N McKillop, Edward Stepanski, Gregory A Vidal, Janeane N Anderson, Lee S Schwartzberg

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cancer survivorship : research and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 10 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 10 syntheses or guidelines pooled it, 108 citations in OpenAlex.

  1. Effectiveness of eHealth interventions in long-term follow-up care for breast and gynecological cancer survivors: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Pooled it
  3. Effectiveness of ePRO-based symptom management for cancer patients: a systematic review and meta-analysis of randomized controlled studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  4. Effectiveness of mHealth apps on adherence and symptoms to oral anticancer medications: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  5. A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Remote symptom monitoring integrated into electronic health records: A systematic review.Journal of the American Medical Informatics Association : JAMIA · 2020
    Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ilana GraetzDepartment of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN, 38163, USA. igraetz@uthsc.edu.ORCID 0000-0003-3664-5815
Caitlin N McKillopDepartment of Economics, State University of New York at Cortland, 28 Graham Ave., Cortland, NY, 13045, USA.
Edward StepanskiDepartment of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN, 38163, USA.
Gregory A VidalDepartment of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN, 38163, USA.
Janeane N AndersonDepartment of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN, 38163, USA.
Lee S SchwartzbergDepartment of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN, 38163, USA.
University of Tennessee Health Science Center · USSUNY Cortland · US

Funding

Effect of patient-provider sexual communication adjuvant endocrine therapy adherence, sexual dysfunction management, and sexual quality of life among Black women with breast cancerR01CA218155 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI GRAETZ, ILANA · 2017 to 2021
$2.3M
NCI NIH HHS R01 CA218155
6 · The paper itself

Abstract

purposeFor postmenopausal women with hormone receptor-positive breast cancer, long-term use of aromatase inhibitors (AIs) significantly reduces the risk of cancer recurrence and improves survival. Still, many patients are nonadherent due to adverse side effects. We conducted a pilot randomized controlled trial to test the use of a web-based application (app) designed with and without weekly reminders for patients to report real-time symptoms and AI use outside of clinic visits with built-in alerts to patients' oncology providers. Our goal was to improve symptom burden and medication adherence.

methodsForty-four women with early-stage breast cancer and a new AI prescription were randomized to either an App+Reminder (weekly reminders to use app) or an App (no reminders) group. Pre- and post-assessment data were collected from all participants.

resultsParticipants in the App+Reminder group had higher weekly app usage rate (74 vs. 38%, p < 0.05) during the intervention and reported higher AI adherence at 8 weeks (100 vs. 72%, p < 0.05). Symptom burden increase was higher for the App group compared to the App+Reminder group but did not reach statistical significance.

conclusionsWeekly reminders to use a web-based app to report AI adherence and treatment-related symptoms demonstrated feasibility and improved short-term AI adherence, which may reduce symptom burden for women with breast cancer and a new AI prescription. IMPLICATIONS FOR CANCER SURVIVORS: If short-term gains in adherence persist, this low-cost intervention could improve survival outcomes for women with breast cancer. A larger, long-term study should examine if AI adherence and symptom burden improvements persist for a 5-year treatment period.

Indexed as

Drug MonitoringInternetMobile ApplicationsAdultAgedAromatase InhibitorsBreast NeoplasmsDrug-Related Side Effects and Adverse ReactionsElectronic Health RecordsFeasibility StudiesFemaleHumansMiddle AgedNeoplasm Recurrence, LocalPatient Reported Outcome MeasuresPilot ProjectsAromatase InhibitorsAromatase inhibitorHealthHormone-receptor positive breast cancerPatient reported outcomesRandomized controlled trial

Identifiers

PMID29492753
PMCPMC6054536
OpenAlexW2791567669

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.